Revolution Medicines awarded FDA National Priority Voucher for daraxonrasib (RMC-6236), a breakthrough RAS inhibitor targeting pancreatic and lung cancer in Phase 3 trials.
XORTX Therapeutics announces $3M acquisition of VB4-P5, a novel anti-fibrotic compound targeting kidney disease, expanding its renal therapy pipeline.
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Disc Medicine receives FDA's Commissioner's National Priority Voucher for bitopertin, accelerating approval timeline to 1-2 months for EPP patients who suffer severe sun sensitivity.
President Trump announces new employer-focused IVF initiative to reduce fertility treatment costs. Voluntary program aims to expand workplace coverage options.
Praxis Precision Medicines stock rallied over 170% after its experimental essential tremor treatment ulixacaltamide exceeded expectations in two Phase 3 trials, defying earlier pessimism.
